Empowered Funds LLC Has $12.74 Million Holdings in Pediatrix Medical Group, Inc. $MD

Empowered Funds LLC trimmed its position in shares of Pediatrix Medical Group, Inc. (NYSE:MD) by 4.3% during the first quarter, Holdings Channel.com reports. The institutional investor owned 595,510 shares of the company’s stock after selling 26,870 shares during the period. Empowered Funds LLC’s holdings in Pediatrix Medical Group were worth $12,738,000 as of its most recent SEC filing.

Other large investors have also recently added to or reduced their stakes in the company. Quantinno Capital Management LP increased its stake in shares of Pediatrix Medical Group by 23.4% during the 1st quarter. Quantinno Capital Management LP now owns 22,928 shares of the company’s stock worth $490,000 after purchasing an additional 4,343 shares during the last quarter. Lazard Asset Management LLC increased its position in Pediatrix Medical Group by 22.1% during the first quarter. Lazard Asset Management LLC now owns 168,979 shares of the company’s stock worth $3,614,000 after buying an additional 30,621 shares during the last quarter. Renaissance Technologies LLC raised its stake in Pediatrix Medical Group by 12.9% in the first quarter. Renaissance Technologies LLC now owns 1,532,300 shares of the company’s stock valued at $32,776,000 after buying an additional 174,600 shares during the period. Cetera Investment Advisers lifted its position in shares of Pediatrix Medical Group by 20.3% in the first quarter. Cetera Investment Advisers now owns 20,213 shares of the company’s stock valued at $432,000 after buying an additional 3,405 shares during the last quarter. Finally, First Trust Advisors LP lifted its position in shares of Pediatrix Medical Group by 4.6% in the first quarter. First Trust Advisors LP now owns 152,876 shares of the company’s stock valued at $3,270,000 after buying an additional 6,769 shares during the last quarter. Institutional investors and hedge funds own 97.71% of the company’s stock.

Wall Street Analyst Weigh In

MD has been the topic of a number of research analyst reports. Truist Financial increased their price target on Pediatrix Medical Group from $23.00 to $28.00 and gave the company a “hold” rating in a research note on Tuesday, July 14th. Jefferies Financial Group restated a “buy” rating and set a $27.00 target price on shares of Pediatrix Medical Group in a research note on Monday, April 20th. Mizuho set a $24.00 target price on shares of Pediatrix Medical Group in a report on Friday, May 8th. Weiss Ratings reissued a “hold (c+)” rating on shares of Pediatrix Medical Group in a report on Wednesday, June 24th. Finally, UBS Group boosted their price objective on Pediatrix Medical Group from $22.00 to $25.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. One analyst has rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $23.33.

Pediatrix Medical Group Price Performance

NYSE:MD opened at $26.75 on Thursday. Pediatrix Medical Group, Inc. has a 52 week low of $11.84 and a 52 week high of $27.94. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.33 and a current ratio of 1.33. The firm’s 50-day simple moving average is $24.40 and its 200 day simple moving average is $22.44. The firm has a market cap of $2.20 billion, a price-to-earnings ratio of 12.98 and a beta of 0.66.

Pediatrix Medical Group (NYSE:MD) last posted its quarterly earnings data on Tuesday, May 5th. The company reported $0.44 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.37 by $0.07. Pediatrix Medical Group had a net margin of 9.02% and a return on equity of 19.94%. The firm had revenue of $476.20 million during the quarter, compared to the consensus estimate of $465.83 million. During the same quarter in the previous year, the firm posted $0.33 EPS. The business’s revenue for the quarter was up 3.9% compared to the same quarter last year. As a group, sell-side analysts predict that Pediatrix Medical Group, Inc. will post 2.1 earnings per share for the current year.

Insider Buying and Selling

In other Pediatrix Medical Group news, Director Shirley A. Weis sold 36,028 shares of Pediatrix Medical Group stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $23.75, for a total value of $855,665.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 1.80% of the stock is currently owned by company insiders.

Pediatrix Medical Group Profile

Pediatrix Medical Group, Inc (NYSE:MD) is a national physician-led medical group specializing in high-acuity newborn, maternal-fetal and pediatric subspecialty care. Headquartered in Sunrise, Florida, the company delivers clinical services through hospital-based physician staffing, advanced practitioner support and telemedicine programs. Its core specialties include neonatology, maternal-fetal medicine, pediatric cardiology, pediatric critical care, pediatric emergency medicine and anesthesiology.

Founded in 1979 and formerly known as MEDNAX, the company rebranded as Pediatrix Medical Group in 2022 to align its corporate identity with its primary clinical offerings.